What is Creso Pharma?
Creso Pharma Limited is a global entity focused on the development, registration, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products. The company targets both human and animal health sectors across Europe, the Middle East, North America, and the Asia Pacific. Its product portfolio includes therapeutic treatments, cultivated cannabis, and processed cannabis products, alongside retail offerings. Key products such as anibidiol for companion animals, cannaQIX for stress reduction, and CBD-based topical skincare solutions highlight the company's diverse market approach. Established in 2015 and headquartered in Nedlands, Australia, Creso Pharma is navigating the complex regulatory landscape to bring innovative health solutions to market.
How much funding has Creso Pharma raised?
Creso Pharma has raised a total of $9M across 1 funding round:
Other Financing Round
$9M
Other Financing Round (2020): $9M with participation from Adam Blumenthal
Key Investors in Creso Pharma
Adam Blumenthal
Adam Blumenthal is an individual investor who participated in the funding round. Further details on their investment focus are not publicly available.
What's next for Creso Pharma?
The recent major strategic investment signals a pivotal phase for Creso Pharma, likely enabling accelerated product development, expanded market penetration, and enhanced research initiatives. This capital infusion is expected to fuel the company's growth in the pharmaceutical-grade cannabis and hemp-derived nutraceuticals sector, positioning it for further scaling and potential future funding rounds. The company's focus on both human and animal health, coupled with its international presence, suggests a strategy aimed at capturing significant market share in a rapidly evolving industry.
See full Creso Pharma company page
